Cargando…

Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study

BACKGROUND: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro-Vega, Yanink, Rebeiro, Peter F., Shepherd, Bryan E., Belaunzarán-Zamudio, Pablo F., Crabtree-Ramirez, Brenda, Cesar, Carina, Luz, Paula Mendes, Cortes, Claudia P., Padget, Denis, Gotuzzo, Eduardo, McGowan, Catherine C., Sierra-Madero, Juan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121860/
https://www.ncbi.nlm.nih.gov/pubmed/35602655
http://dx.doi.org/10.1016/j.lana.2021.100175
_version_ 1784711231942164480
author Caro-Vega, Yanink
Rebeiro, Peter F.
Shepherd, Bryan E.
Belaunzarán-Zamudio, Pablo F.
Crabtree-Ramirez, Brenda
Cesar, Carina
Luz, Paula Mendes
Cortes, Claudia P.
Padget, Denis
Gotuzzo, Eduardo
McGowan, Catherine C.
Sierra-Madero, Juan G.
author_facet Caro-Vega, Yanink
Rebeiro, Peter F.
Shepherd, Bryan E.
Belaunzarán-Zamudio, Pablo F.
Crabtree-Ramirez, Brenda
Cesar, Carina
Luz, Paula Mendes
Cortes, Claudia P.
Padget, Denis
Gotuzzo, Eduardo
McGowan, Catherine C.
Sierra-Madero, Juan G.
author_sort Caro-Vega, Yanink
collection PubMed
description BACKGROUND: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between cumulative percentage of time with CD4 <200 cells/µL during viral suppression (VS) (%t(CD4<200)), and mortality and comorbidities during 2000-2019. METHODS: In a retrospective cohort analysis, we followed PWH initiating ART in Latin America from first VS (HIV-RNA<200 copies/µL) to death, virological failure or loss to follow-up. We fit Cox models to estimate risk of death and/or AIDS-defining and serious non-AIDS-defining events (ADE and SNADE -cancer, cardiovascular, liver, and renal diseases) by %t(CD4<200) (continuous variable). We predicted survival probabilities for each event and calculated risks of hypothetical cases of different %t(CD4<200). FINDINGS: In 8,369 patients with 34·9 months of follow-up (median, IQR: 16·7, 69·1), 4,274 (51%) started ART with CD4<200 cells/µL. Median %t(CD4<200) was 0% (IQR: 0, 15%). We identified 195 (2·3%) deaths and 584 (7·2%) patients with ADE/SNADE. For an increased %t(CD4<200) of 15% (e.g., 15% vs. 0%), the adjusted relative hazard (aHR) of death was 1·27 (95% confidence interval [CI]: 1·19 – 1·35), of ADE/SNADE was 1·13 (95%CI: 1·09 – 1·17), of SNADE was 0·96 (95%CI: 0·89 – 1·02) and of death/ADE/SNADE was 1·11 (95%CI: 1·07 – 1·14). Estimates were similar after adjusting for time updated CD4 count. INTERPRETATION: In virologically suppressed PWH, increased time living with severe immunosuppression had an increased risk of death and ADE/SNADE in this Latin American cohort, independently of time updated CD4 count. FUNDING: This work was supported by the NIH-funded Caribbean, Central and South America network for HIV epidemiology (CCASAnet, U01AI069923), a member cohort of the International Epidemiologic Databases to Evaluate AIDS (leDEA). This award is funded by the following institutes: Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Cancer Institute (NCI), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Mental Health (NIMH), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Fogarty International Center (FIC). Specific funding was provided from the Fogarty International Center (FIC) for lead author, Yanink Caro-Vega, for the Fogarty-IeDEA Mentorship Program (FIMP).
format Online
Article
Text
id pubmed-9121860
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91218602022-05-20 Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study Caro-Vega, Yanink Rebeiro, Peter F. Shepherd, Bryan E. Belaunzarán-Zamudio, Pablo F. Crabtree-Ramirez, Brenda Cesar, Carina Luz, Paula Mendes Cortes, Claudia P. Padget, Denis Gotuzzo, Eduardo McGowan, Catherine C. Sierra-Madero, Juan G. Lancet Reg Health Am Articles BACKGROUND: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between cumulative percentage of time with CD4 <200 cells/µL during viral suppression (VS) (%t(CD4<200)), and mortality and comorbidities during 2000-2019. METHODS: In a retrospective cohort analysis, we followed PWH initiating ART in Latin America from first VS (HIV-RNA<200 copies/µL) to death, virological failure or loss to follow-up. We fit Cox models to estimate risk of death and/or AIDS-defining and serious non-AIDS-defining events (ADE and SNADE -cancer, cardiovascular, liver, and renal diseases) by %t(CD4<200) (continuous variable). We predicted survival probabilities for each event and calculated risks of hypothetical cases of different %t(CD4<200). FINDINGS: In 8,369 patients with 34·9 months of follow-up (median, IQR: 16·7, 69·1), 4,274 (51%) started ART with CD4<200 cells/µL. Median %t(CD4<200) was 0% (IQR: 0, 15%). We identified 195 (2·3%) deaths and 584 (7·2%) patients with ADE/SNADE. For an increased %t(CD4<200) of 15% (e.g., 15% vs. 0%), the adjusted relative hazard (aHR) of death was 1·27 (95% confidence interval [CI]: 1·19 – 1·35), of ADE/SNADE was 1·13 (95%CI: 1·09 – 1·17), of SNADE was 0·96 (95%CI: 0·89 – 1·02) and of death/ADE/SNADE was 1·11 (95%CI: 1·07 – 1·14). Estimates were similar after adjusting for time updated CD4 count. INTERPRETATION: In virologically suppressed PWH, increased time living with severe immunosuppression had an increased risk of death and ADE/SNADE in this Latin American cohort, independently of time updated CD4 count. FUNDING: This work was supported by the NIH-funded Caribbean, Central and South America network for HIV epidemiology (CCASAnet, U01AI069923), a member cohort of the International Epidemiologic Databases to Evaluate AIDS (leDEA). This award is funded by the following institutes: Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Cancer Institute (NCI), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Mental Health (NIMH), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Fogarty International Center (FIC). Specific funding was provided from the Fogarty International Center (FIC) for lead author, Yanink Caro-Vega, for the Fogarty-IeDEA Mentorship Program (FIMP). Elsevier 2022-01-13 /pmc/articles/PMC9121860/ /pubmed/35602655 http://dx.doi.org/10.1016/j.lana.2021.100175 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Caro-Vega, Yanink
Rebeiro, Peter F.
Shepherd, Bryan E.
Belaunzarán-Zamudio, Pablo F.
Crabtree-Ramirez, Brenda
Cesar, Carina
Luz, Paula Mendes
Cortes, Claudia P.
Padget, Denis
Gotuzzo, Eduardo
McGowan, Catherine C.
Sierra-Madero, Juan G.
Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
title Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
title_full Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
title_fullStr Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
title_full_unstemmed Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
title_short Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
title_sort clinical effects of durability of immunosuppression in virologically suppressed art-initiating persons with hiv in latin america. a retrospective cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121860/
https://www.ncbi.nlm.nih.gov/pubmed/35602655
http://dx.doi.org/10.1016/j.lana.2021.100175
work_keys_str_mv AT carovegayanink clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT rebeiropeterf clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT shepherdbryane clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT belaunzaranzamudiopablof clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT crabtreeramirezbrenda clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT cesarcarina clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT luzpaulamendes clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT cortesclaudiap clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT padgetdenis clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT gotuzzoeduardo clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT mcgowancatherinec clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy
AT sierramaderojuang clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy